AB
ABVX.US Abivax SA American Depositary Shares
- Market cap
- USD 7.90B
- P/E
- -
- P/B
- 19.48x
- ROE
- -90.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ABVX.US undervalued?
Graham numberThe Graham number of Abivax SA American Depositary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abivax SA American Depositary Shares fundamental analysis
No fundamental analysis for Abivax SA American Depositary Shares yet.
Abivax SA American Depositary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in…
Full company profileAbivax SA American Depositary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Abivax SA American Depositary Shares annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 127K | 10.0K | 18.0K | 2.00K | 63.0K | 37.0K | 4.58M | 4.62M | 10.8M | 0.00 | 0.00 |
| Gross Profit | -14.5M | -14.5M | -15.4M | -28.2M | -33.8M | -45.5M | -50.8M | 4.57M | 10.8M | -1.03M | - |
| Operating Income | -18.2M | -14.2M | -19.1M | -33.3M | -38.0M | -41.4M | -64.8M | -127M | -173M | -246M | -281M |
| EBITDA | -17.9M | -14.0M | -19.2M | -33.2M | -38.0M | -38.6M | -53.3M | -133M | -163M | -301M | -335M |
| Net Income | -14.3M | -11.2M | -15.8M | -30.6M | -37.6M | -42.5M | -60.7M | -148M | -176M | -336M | -332M |
| EPS | -1.47 | -1.13 | -1.55 | -2.51 | -2.62 | -2.75 | -3.18 | -3.43 | -2.80 | -4.83 | -4.17 |
| Balance Sheet | |||||||||||
| Total Assets | 60.6M | 53.8M | 54.0M | 51.7M | 71.3M | 109M | 75.5M | 327M | 205M | 584M | 462M |
| Total Liabilities | 3.88M | 5.64M | 19.4M | 33.1M | 53.4M | 83.3M | 68.4M | 131M | 165M | 129M | 95.9M |
| Shareholders' Equity | 56.7M | 48.2M | 34.7M | 18.6M | 17.9M | 25.9M | 7.19M | 196M | 40.6M | 455M | 366M |
| Cash & Short-term Investments | 23.0M | 17.0M | 13.0M | 9.77M | 29.3M | 60.7M | 27.0M | 261M | 144M | 530M | 411M |
| Total Debt | 316K | 262K | 10.9M | 20.7M | 34.0M | 51.7M | 39.2M | 58.0M | 97.4M | 45.9M | 1.21M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.6M | -8.45M | -14.6M | -27.5M | -29.8M | -45.0M | -53.9M | -100M | -154M | -156M | -205M |
| Capital Expenditure | 721K | 979K | 763K | 941K | 898K | 47.0K | 323K | 265K | 643K | 136K | 332K |
| Free Cash Flow | -16.3M | -9.43M | -15.4M | -28.4M | -30.7M | -45.1M | -54.3M | -100M | -155M | -156M | -205M |
| Ratios | |||||||||||
| ROE | -25.2% | -23.3% | -45.7% | -164.8% | -209.8% | -163.7% | -844.9% | -75.4% | -434.3% | -73.9% | -90.6% |
| ROA | -23.6% | -20.9% | -29.3% | -59.2% | -52.7% | -38.9% | -80.4% | -45.2% | -85.9% | -57.5% | -71.8% |
| Net Profit Margin | -11,266.1% | -112,230.0% | -87,905.6% | -1,531,700.0% | -59,604.8% | -114,735.1% | -1,325.3% | -3,197.1% | -1,633.1% | - | - |
| Debt to Equity | 0.01x | 0.01x | 0.31x | 1.12x | 1.90x | 1.99x | 5.45x | 0.30x | 2.40x | 0.10x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Abivax SA American Depositary Shares dividends
Abivax SA American Depositary Shares has not paid dividends in the last 9 fiscal years.
Who owns Abivax SA American Depositary Shares
- Insiders 0.00%
- Institutions 71.71%
- Public & others 28.29%
- Shares outstanding 87.5M
- Free float 65.0M
Top funds holding ABVX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Alger Focus Equity I | 608K | 0.69% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 565K | 0.65% | -0.42% | Oct 2026 |
| HBM Healthcare Investments AG Ord | 408K | 0.47% | +31.60% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 395K | 0.45% | +23.25% | Jun 2026 |
| Harbor Small Cap Growth Instl | 357K | 0.41% | +21.71% | Sep 2026 |
| Alger Spectra A | 334K | 0.38% | 0.00% | Aug 2026 |
| Worldwide Healthcare Ord | 321K | 0.37% | +42.32% | Jul 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 276K | 0.32% | +47.41% | Jun 2026 |
| Janus Henderson Global Life Sciences D | 270K | 0.31% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 263K | 0.30% | +11.76% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 259K | 0.30% | +6.29% | Aug 2026 |
| Alger Capital Appreciation Instl I | 241K | 0.28% | -7.24% | Aug 2026 |
| Pictet-Biotech P USD | 231K | 0.26% | +0.38% | Jul 2026 |
| abrdn World Healthcare | 230K | 0.26% | +9.46% | Sep 2026 |
| abrdn Healthcare Investors | 216K | 0.25% | 0.00% | Sep 2026 |
| Alger Capital Appreciation A | 201K | 0.23% | -3.65% | Aug 2026 |
| Pictet-Global Megatrend Sel I USD | 198K | 0.23% | -3.22% | Jul 2026 |
| Franklin Biotechnology Discv A(acc)USD | 191K | 0.22% | 0.00% | Sep 2026 |
| abrdn Healthcare Opportunities | 157K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 146K | 0.17% | 0.00% | Aug 2026 |
Top institutions holding ABVX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 6.01M | 6.86% | -7.30% | Jun 2026 |
| Darwin Global Management, Ltd. | 3.62M | 4.14% | +4.41% | Jun 2026 |
| Helikon Investments Ltd | 2.79M | 3.18% | +175.05% | Jun 2026 |
| Vestal Point Capital LP | 2.35M | 2.68% | +56.63% | Jun 2026 |
| Jupiter Topco LLC | 1.91M | 2.19% | 0.00% | Jun 2026 |
| UBS Group AG | 1.84M | 2.11% | -59.43% | Jun 2026 |
| ADAR1 Capital Management LLC | 1.80M | 2.06% | +29.46% | Jun 2026 |
| Caligan Partners LP | 1.56M | 1.78% | +6.57% | Jun 2026 |
| Citadel Advisors Llc | 1.44M | 1.64% | +164.24% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.43M | 1.64% | -16.00% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 1.31M | 1.50% | -0.99% | Jun 2026 |
| RA Capital Management, LLC | 1.13M | 1.29% | 0.00% | Jun 2026 |
| NORGES BANK | 1.10M | 1.26% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 1.05M | 1.20% | +176.41% | Jun 2026 |
| Logos Global Management LP | 1.02M | 1.17% | +51.70% | Jun 2026 |
| Octagon Capital Advisors LP | 993K | 1.13% | +46.68% | Jun 2026 |
| Bank of America Corp | 971K | 1.11% | +32.04% | Jun 2026 |
| Eversept Partners, LP | 914K | 1.04% | -2.20% | Jun 2026 |
| The Goldman Sachs Group Inc | 793K | 0.91% | +127.27% | Jun 2026 |
| Cormorant Asset Management, LLC | 675K | 0.77% | -11.18% | Jun 2026 |
Abivax SA American Depositary Shares company profile
- Company name
- Abivax SA American Depositary Shares
- Ticker
- ABVX.US
- Exchange
- USA Stocks
- Listed since
- Oct 20, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 98
- Fiscal year end
- December
- Address
- 7-11 Boulevard Haussmann, Paris, France, 75009
- Phone
- 33 1 53 83 09 63
- Website
- abivax.com
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Abivax SA American Depositary Shares management
10- Mr. Marc M. P. de Garidel M.B.A.CEO & Director · born 1958
- Mr. Didier BlondelEVP, CFO & Board Secretary · born 1964
- Mr. Timothy P. Kelly M.B.A.Chief Technical Officer · born 1969
- Mr. Patrick MalloySenior VP & Head of Investor Relations
- Ms. Ida HatoumChief People & Compliance Officer · born 1975
- Mr. James BergerGlobal Head of Marketing
- Mr. Pierre Courteille M.B.A.Chief Business Officer · born 1969
- Hema KeshavaSenior Vice President of Finance
- Mr. Chris Rabbat Ph.D.Chief Medical Officer
- Kevin Shan Ph.D.VP & Global Head of Biometrics